Free Trial

Stevanato Group Q1 2024 Earnings Report

Stevanato Group logo
€20.26 -0.72 (-3.43%)
As of 03/27/2025 03:58 PM Eastern

Stevanato Group EPS Results

Actual EPS
€0.09
Consensus EPS
€0.12
Beat/Miss
Missed by -€0.03
One Year Ago EPS
N/A

Stevanato Group Revenue Results

Actual Revenue
$256.24 million
Expected Revenue
$261.28 million
Beat/Miss
Missed by -$5.04 million
YoY Revenue Growth
N/A

Stevanato Group Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Stevanato Group Earnings Headlines

Stevanato Group management to meet with Stephens
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Stevanato: Ramping Syringe Demand, Buy Confirmed
See More Stevanato Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stevanato Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stevanato Group and other key companies, straight to your email.

About Stevanato Group

Stevanato Group (NYSE:STVN) engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

View Stevanato Group Profile

More Earnings Resources from MarketBeat